With Australia's cash rate now at a 15-year high, money in the bank finally pays something again, but inflation and higher borrowing costs still eat into real wealth. That is why investors are paying closer attention to companies with solid returns on equity, resilient balance sheets and a history of holding up under pressure. This article highlights three such Australian stocks drawn from that quality focused group.
The three examples in this piece are only a starting sample from that quality focused group. The full screen surfaced 8 more companies with similarly compelling fundamentals and balance sheets that are not covered here. To see the complete set, analyze, filter and identify your own high conviction ideas straight from the Solid Balance Sheet and Fundamentals screener .
Pro Medicus (ASX:PME)
Overview:Pro Medicus provides enterprise medical imaging and radiology information software, with its Visage suite driving recurring revenue and supporting high returns on equity.
Operations:Pro Medicus generates A$261.69 million from integrated healthcare imaging software, with most revenue coming from Australia and North America hospital clients.
Market Cap:A$17.11b
Pro Medicus matters for this screener because its Visage imaging platform converts mission critical hospital workflows into sticky, recurring software income backed by a clean balance sheet.
"Radiologists at top US hospitals have started demanding it as a condition of employment; they simply won't join institutions that don't run Visage, the company's flagship imaging platform. Once embedded in a hospital's clinical workflow, the switching costs are enormous: replacing a PACS system means retraining every radiologist, migrating years of archived images, and disrupting a mission-critical clinical function."
What happens to that high margin, high return profile if a single unseen pressure shifts how hospitals value speed versus cost in imaging software?
If that question is on your mind, read the full narrative for Pro Medicus to see whether those switching costs are masking risk or accelerating Pro Medicus' advantage.
Resolute Mining (ASX:RSG)
Overview:Resolute Mining is a Perth based gold producer focused on African mines that generate cash flow from operating assets and growth projects.
Operations:Resolute Mining reports about $696 million of revenue from the Syama mine in Mali and $307 million from the Mako mine in Senegal.
Market Cap:A$2.51b
Resolute Mining matters for a solid balance sheet screen because cash flow from its Syama, Mako and Doropo linked assets underpins both returns on equity and the financial capacity to fund new projects without stretching the balance sheet.
"The Doropo, ABC, and La Debo projects in Côte d'Ivoire, alongside the Syama Sulphide Conversion Project and life extension at Mako (through Bantaco and Tomboronkoto), are expected to significantly increase production volumes to over 500,000 ounces by 2028, driving sustained top-line growth and greater economies of scale that can enhance profitability."
What happens to those high level margin ambitions if a single key assumption about operating stability or cost discipline starts to crack?
If that pressure point worries you, read the full narrative for Resolute Mining to see whether those assumptions are masking fragility or setting up an underappreciated acceleration.
Codan (ASX:CDA)
Overview:Codan develops communications systems and high margin metal detection equipment for gold prospecting, demining and military users worldwide, supported by a solid balance sheet.
Operations:Codan generates about A$506 million from Communications and A$362 million from Metal Detection, with revenue spread across the United States, United Arab Emirates and other regions.
Market Cap:A$11.72b
Codan matters for a solid balance sheet and fundamentals screen because its Metal Detection arm pairs high return niche products with recurring aftermarket demand, while the Communications unit broadens cash flow and supports reinvestment into growth.
"Rising global regulatory pressure and compliance costs surrounding supply chain transparency and electronic waste are likely to increase Codan's operational expenses over the long term, potentially eroding net margins and raising ongoing cost of doing business."
The real test for Codan is what happens to that high return profile if a single assumption about acquisition discipline or pricing power breaks.
When that assumption breaks or holds, the full narrative for Codan lays out how Codan's acquisition playbook, pricing power and cash generation could be quietly accelerating.
Curious About What You Might Be Missing Next
Fresh ideas move first. By the time momentum is obvious, entry points can be flying away. Scan curated shortlists before they leave the under the radar for now crowd.
-
Look for smaller opportunities with sharp balance sheets and strong financials using the curated 17 elite penny stocks with strong financials .
-
Follow early AI momentum by scanning the focused 9 AI small caps that are exposed to demand for real world machine learning infrastructure.
-
Review payout strength with the curated 3 dividend fortresses where yields, cash flows and balance sheets currently align.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
